01—Abstract
Summary
Summary of the 10-K filed February 11, 2021. Cited figures are marked; the original filing is the authoritative source.
Vertex Pharmaceuticals' FY2020 10-K shows a company that has transitioned into a highly profitable, cash-generating business on the back of its cystic fibrosis (CF) franchise.
Total revenues rose 49% to $6.21 billiona, driven by product revenues of $6.20 billion, with TRIKAFTA/KAFTRIO alone contributing $3.86 billion (up from $420 million in 2019). Income from operations more than doubled to $2.86 billion, and net income attributable to Vertex reached $2.71 billion, or $10.29 per diluted share, versus $4.51 in 2019. Results were also helped by $312 million of gains on strategic equity investments, and 2020 included a 13% effective tax rate aided by a one-time $209 million intellectual property transfer to the U.K.
Operating cash flow was $3.25 billionb. The key investor consideration is concentration risk. Substantially all revenue and the most advanced clinical assets relate to CF, and the filing explicitly ties future growth to TRIKAFTA uptake in ex-U.S. markets, reimbursement progress, and label expansion into younger children (an sNDA for ages 6 to 11 was accepted with Priority Review in January 2021).
Meanwhile, Vertex is spending heavily on diversification: R&D expense was $1.83 billionc, with pipeline programs in alpha-1 antitrypsin deficiency, APOL1-mediated kidney disease, pain, and cell and genetic therapies (CTX001 for sickle cell disease and beta thalassemia, and type 1 diabetes). Several of these programs are early, and the company discontinued VX-814 in October 2020 on safety grounds. Balance-sheet strength is a clear positive.
Cash, equivalents and marketable securities reached $6.66 billiond, working capital was $6.3 billion, the company has $2.5 billion of undrawn revolving credit, and it repurchased $539 million of stock in 2020 with $425 million remaining under its authorization. Management expects product cash flows and existing cash to fund operations for at least twelve months. Investors should watch the pace of TRIKAFTA's ex-U.S. reimbursement, the outcome of the pediatric filing, the rising cash tax burden as NOLs are used up, and the volatility introduced by strategic equity holdings.
02—Key points
Key Highlights
- Total revenues grew 49% to $6.21B in 2020, with product revenues of $6.20B; TRIKAFTA/KAFTRIO generated $3.86B, more than nine times its 2019 level.
- Net income attributable to Vertex rose 130% to $2.71B ($10.29 diluted EPS), helped by $312M of gains on strategic equity investments and a 13% effective tax rate.
- Income from operations increased 139% to $2.86B, while R&D ($1.83B) and SG&A ($770M) grew more modestly, indicating operating leverage.
- Cash, cash equivalents and marketable securities totaled $6.66B at year-end, up $2.85B, with operating cash flow of $3.25B.
- Concentration risk remains high: substantially all revenue and most advanced clinical programs are tied to CF, and key growth depends on ex-U.S. reimbursement and pediatric label expansion.
- Pipeline catalysts for 2021 include VX-864 Phase 2 data (AAT deficiency), VX-147 Phase 2 data (APOL1-mediated FSGS), CTX001 enrollment completion, and initiation of the VX-880 type 1 diabetes trial.
- Capital returns: $539M of share repurchases in 2020 and a new $500M authorization running through December 2022 ($425M remaining at year-end).
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2020, Vertex Pharmaceuticals Inc kept $0.44.
- Revenue$6.21B100.0%
- Cost of revenue−$736.3M11.9%
- Gross profit$5.47B88.1%
- Operating costs−$2.61B42.1%
- Operating income$2.86B46.0%
- Interest, other & tax−$144.6M2.3%
- Net income$2.71B43.7%
Where FY2020 revenue went
$6.21B- Net income: $2.71B, 44% of revenue
- R&D: $1.83B, 29% of revenue
- SG&A: $770.5M, 12% of revenue
- Cost of revenue: $736.3M, 12% of revenue
- Interest, other & tax: $144.6M, 2.3% of revenue
Kept 44% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2020filed February 11, 2021Financial Statements
FY2020 against FY2019
| Line item | FY2020FY2019 | Change |
|---|---|---|
| Revenue | $6.21B$4.16B | +49.1% |
| Cost of Revenue | $736.30M$547.80M | +34.4% |
| Gross Profit | $5.47B$3.62B | +51.3% |
| R&D Expenses | $1.83B$1.75B | +4.3% |
| SG&A Expenses | $770.50M$658.50M | +17.0% |
| Operating Expenses | $3.35B$2.97B | +13.0% |
| Operating Income | $2.86B$1.20B | +138.5% |
| Interest Expense | $58.15M$58.50M | −0.6% |
| Net Income | $2.71B$1.18B | +130.4% |
| EPS (Basic) | $10.44$4.58 | +127.9% |
| EPS (Diluted) | $10.29$4.51 | +128.2% |
| Shares Outstanding (Basic) | 259.80M256.70M | +1.2% |
| Shares Outstanding (Diluted) | 263.40M260.70M | +1.0% |
05—Questions
Frequently Asked Questions
How dependent is Vertex on its cystic fibrosis medicines?
Almost entirely. All product revenue and the vast majority of total revenue come from CF medicines (TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI, KALYDECO). The company says its most advanced drug candidates also relate to CF, so a competitive setback, reimbursement pressure, or safety issue in CF would have a outsized impact on the business.
What drove the large increase in 2020 revenue and earnings?
The main driver was TRIKAFTA/KAFTRIO, which was approved in the U.S. in late 2019 and in the E.U. in 2020 (as KAFTRIO). Product revenue rose $2.04B to $6.20B. Other income also contributed, with $296M of net other income, mostly from fair value gains on strategic equity holdings such as CRISPR Therapeutics. The 2020 tax provision benefited from a one-time $209M intellectual property transfer to the U.K.
What are the main near-term growth catalysts?
Key items include the FDA's Priority Review of the TRIKAFTA sNDA for children aged 6 to 11, Health Canada's review of TRIKAFTA for ages 12 and older, continued ex-U.S. uptake and reimbursement expansion, and 2021 data readouts for VX-864 (AAT deficiency) and VX-147 (APOL1-mediated FSGS). Management expects net product revenue to increase in 2021, with R&D and SG&A also rising.
Is Vertex's balance sheet and capital allocation position strong?
Yes. The company ended 2020 with $6.66B in cash and marketable securities, $6.3B of working capital, and undrawn revolving credit facilities totaling $2.5B. It repurchased $539M of stock during the year and has $425M left on its 2020 authorization. Management says existing cash and product cash flow will fund operations for at least the next 12 months.
What risks should investors weigh most heavily?
The main risks are: (1) concentration in CF, including the possibility of competing therapies; (2) pricing and reimbursement pressure in the U.S. and abroad, including the Medicaid rebate and drug-pricing policy environment; (3) the early and uncertain nature of the pipeline, including the VX-814 discontinuation; (4) limited experience with cell and genetic therapies and their manufacturing; (5) patent litigation, including a Paragraph IV challenge from Sun Pharma to KALYDECO's '481 patent; and (6) earnings volatility from strategic equity investments and a rising cash tax burden as net operating losses are used up.
06—Continue